Hypoglycemia in Diabetes
Гипогликемия при сахарном диабете
2003-06-01
SCID: 54.1/mqs5q7p7
Discuss with AI
glucose counterregulationhypoglycemia unawarenesshypoglycemia-associated autonomic failureiatrogenic hypoglycemiatype 1 diabetes
Figures from the paper
Abstract (AI)
Iatrogenic hypoglycemia causes recurrent morbidity in most people with type 1 diabetes and many with type 2 diabetes, and it is sometimes fatal. The barrier of hypoglycemia generally precludes maintenance of euglycemia over a lifetime of diabetes and thus precludes full realization of euglycemia's long-term benefits. While the clinical presentation is often characteristic, particularly for the experienced individual with diabetes, the neurogenic and neuroglycopenic symptoms of hypoglycemia are nonspecific and relatively insensitive; therefore, many episodes are not recognized. Hypoglycemia can result from exogenous or endogenous insulin excess alone. However, iatrogenic hypoglycemia is typically the result of the interplay of absolute or relative insulin excess and compromised glucose counterregulation in type 1 and advanced type 2 diabetes. Decrements in insulin, increments in glucagon, and, absent the latter, increments in epinephrine stand high in the hierarchy of redundant glucose counterregulatory factors that normally prevent or rapidly correct hypoglycemia. In insulin-deficient diabetes (exogenous) insulin levels do not decrease as glucose levels fall, and the combination of deficient glucagon and epinephrine responses causes defective glucose counterregulation. Reduced sympathoadrenal responses cause hypoglycemia unawareness. The concept of hypoglycemia-associated autonomic failure in diabetes posits that recent antecedent hypoglycemia causes both defective glucose counterregulation and hypoglycemia unawareness. By shifting glycemic thresholds for the sympathoadrenal (including epinephrine) and the resulting neurogenic responses to lower plasma glucose concentrations, antecedent hypoglycemia leads to a vicious cycle of recurrent hypoglycemia and further impairment of glucose counterregulation. Thus, short-term avoidance of hypoglycemia reverses hypoglycemia unawareness in most affected patients. The clinical approach to minimizing hypoglycemia while improving glycemic control includes 1) addressing the issue, 2) applying the principles of aggressive glycemic therapy, including flexible and individualized drug regimens, and 3) considering the risk factors for iatrogenic hypoglycemia. The latter include factors that result in absolute or relative insulin excess: drug dose, timing, and type; patterns of food ingestion and exercise; interactions with alcohol and other drugs; and altered sensitivity to or clearance of insulin. They also include factors that are clinical surrogates of compromised glucose counterregulation: endogenous insulin deficiency; history of severe hypoglycemia, hypoglycemia unawareness, or both; and aggressive glycemic therapy per se, as evidenced by lower HbA(1c) levels, lower glycemic goals, or both. In a patient with hypoglycemia unawareness (which implies recurrent hypoglycemia) a 2- to 3-week period of scrupulous avoidance of hypoglycemia is advisable. Pending the prevention and cure of diabetes or the development of methods that provide glucose-regulated insulin replacement or secretion, we need to learn to replace insulin in a much more physiological fashion, to prevent, correct, or compensate for compromised glucose counterregulation, or both if we are to achieve near-euglycemia safely in most people with diabetes.
Key Findings
1
Hypoglycemia commonly results from insulin excess interacting with impaired glucose counterregulation, particularly deficient glucagon and epinephrine responses in insulin-deficient diabetes.
2
Iatrogenic hypoglycemia causes recurrent morbidity in most people with type 1 diabetes and many with type 2 diabetes, and can be fatal.
3
Neurogenic and neuroglycopenic symptoms are nonspecific and relatively insensitive, so many hypoglycemic episodes remain unrecognized.
4
Reduced sympathoadrenal responses contribute to hypoglycemia unawareness; antecedent hypoglycemia further lowers sympathoadrenal response thresholds, creating a cycle of recurrent hypoglycemia.
5
Short-term avoidance of hypoglycemia reverses hypoglycemia unawareness in most affected patients.
Research Object
Iatrogenic hypoglycemia in people with type 1 or type 2 diabetes
Research Subject
The mechanisms of defective glucose counterregulation, hypoglycemia unawareness, and recurrent hypoglycemia
Publication Details
Publication Date
2003-06-01
Journal
Publisher
ISSN
Cited by
1337
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus1993
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes2008
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes2010
Blood-to-Brain Glucose Transport, Cerebral Glucose Metabolism, and Cerebral Blood Flow Are Not Increased After Hypoglycemia2001
Cited by7
Guidelines for the Early Management of Patients With Acute Ischemic Stroke2013
Standards of Medical Care in Diabetes—20132012
Standards of Medical Care in Diabetes—20122011
Machine Learning and Data Mining Methods in Diabetes Research2017
Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?2011
Hypoglycemia Prevention via Pump Attenuation and Red-Yellow-Green “Traffic” Lights Using Continuous Glucose Monitoring and Insulin Pump Data2010
National Athletic Trainers' Association Position Statement: Preventing Sudden Death in Sports2012